• By Keng Jin Lee

    Interim findings from a phase 2 trial hint that Glaukos’ travapost intraocular implant may maintain reduced IOP in patients with glaucoma.

    Injected through a clear corneal incision and secured in the anterior chamber, the iDose delivery system releases a steady stream of travapost over an extended time. Once the medication is depleted, the titanium implant can be removed and replaced in a separate procedure.

    The multicenter, randomized, double-masked trial enrolled 154 patients who received fast or slow versions of the iDose delivery system, or a control solution of 0.5% topical timolol. During the trial’s first 12 months, 49 patients in the implant group achieved an approximately 30% reduction in mean IOP from baseline. The mean number of glaucoma medications ranged from 0.54 to 0.56 at 12 months in both iDose arms, compared with 0.72 in the timolol arm.

    The implant’s safety profile remains favorable, with no adverse events of hyperemia reported to date.

    “These latest phase 2 results further underscore the potential of iDose travoprost to provide many months of sustained glaucoma pharmaceutical therapy and tackle the significant problem of patient non-adherence to topical medication regimens,” said Thomas Burns, president and CEO of Glaukos.

    “We are pleased to be working cooperatively with the FDA as we prepare for the phase 3 trial, which will mark another critical step forward in the advancement of our novel and comprehensive product pipeline designed to transform glaucoma therapy,” Burns said.